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INTRODUCTION 
The infant of the diabetic mother is one of the most 
intensively studied yet enigmatic subjects in pediatrics. 
The primary focus of the investigations of these infants 
has been directed toward their tendency to become hypo¬ 
glycemic in the immediate post partum period. From the 
time of Hartmann and Jaudon's article in 1937 (1) through 
the present, inquiries into the frequency and significance 
of neonatal hypoglycemia have been abundant. While there 
have been reports which have denied the predilection for 
hypoglycemia in the IDM (2), the current view of the 
situation is that approximately one half of all infants 
born to diabetic mothers experience a fall in blood glu¬ 
cose levels to below 20 mg/100 ml within the first few 
hours of life (3,^). 
The significance of the fall in glucose has been 
debated.. Several authors have suggested that neonatal 
hypoglycemia is of no clinical significance (5,6). How¬ 
ever, a study by Beard et al (7) has shown that there 
is, in fact, a significant Incidence of brain damage ob¬ 
served in infants who experience neonatal hypoglycemia. 
Additionally, animal models (8) have demonstrated that 
anabolic processes seem to be interfered with during 
periods of hypoglycemia. Studies of the human brain in 
insulin coma have shown that there is a decreased oxygen 
uptake during the hypoglycemic period (9)* A follow-up 
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study of 151 children concluded that symptomatic hypo¬ 
glycemia in newborns was associated with CNS symptoms and 
a poor prognosis, while asymptomatic hypoglycemia was 
not associated with significant morbidity later in life 
(10) . This data has led most investigators to believe 
that it is worthwhile maintaining neonatal normoglycemia 
or at least to prevent the profound hypoglycemia to 
which IDM’s appear prone. 
The cause of the neonatal hypoglycemia is uncertain. 
For some time it was felt that the relative hypoglycemia 
during pregnancy induces islet cell hyperplasia in the 
infant of the diabetic, and that this hyperplasia in 
turn is responsible for a relative or absolute hyper- 
insulinism postnatally. The theory, first proposed in 
the 1920?s by Dubreuii and Anderodias, has been supported 
over the years by observations that infants of diabetic 
mothers have shown islet cell hyperplasia and hypertrophy 
(11) , increased amounts of body fat (12), higher birth 
weights (13), a failure to increase their free fatty 
acids in the neonatal period (14), and finally, neonatal 
hypoglycemia. 
Pederson and others have hypothesized that the hypogly¬ 
cemia of these infants is, in fact, due to a hyperinsulin- 
ism. In support of this theory is evidence which has 
been accumulated which shows that IDM’s demonstrate a 
more rapid disappearance of endogenous glucose if tested 
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shortly after birth. (15) and that when exogenous glucose 
is administered to these infants in the form of an intra¬ 
venous glucose loading test, they also show a more rapid 
decrease than do normal infants (16). 
In opposition to this theory, one must recognise 
that although insulin levels may be increased in infants 
of diabetic mothers, blood sugar levels are also increased. 
The difference between insulin values in infants of 
diabetics and normals disappeared after the age of 2 hours 
(17) coincident to the return of IDM blood sugar levels 
to the range of normals. Furthermore, several workers 
have shown that insulin release is not increased after 
slow IV glucose loads In IDM’s even though they show the 
aforementioned rapid glucose disappearance under other 
circumstances (18). 
In the present study, we have attempted to assess the 
role of the amino acids alinine in the hypoglycemia of 
neonatal IDM’s. Van Slyke and Meyer were the first to 
notice that in a condition of negative nitrogen balance, 
the muscles of animals release free amino acids. By their 
studies in dogs which had been fasted for some time, they 
concluded that muscle tissue protein is the source of 
amino acids (19). Since that time, a great deal of work 
on the mechanisms of alanine release has been done. This 
work culminated in the work of Felig (20) in which he 
postulates "the glucose-alanine cycle." 
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In brief, this theory proposes that alanine acts as 
the substrate for hepatic gluconeogenesis. Since that 
study appeared, much work has been done in the elucidation 
of more precise mechanisms involved in giucostasis. Of 
particular interest to the present study is the work that 
has been done with diabetic patients. It has been shown, 
for example, that the level of alanine is markedly reduced 
in diabetics. This low level returns towards normal with 
the administration of insulin (21-23). This and other 
observations have led to the hypothesis that the hyper¬ 
glycemia seen in diabetes is a function of increased 
hepatic extraction rather than increased substrate availa¬ 
bility (23). Increases in splaunchnic uptake of alanine 
have been observed in diabetics, accounting for approximately 
50% of the glucose output in these individuals (22). This 
increased splaunchnic uptake and therefore, hepatic glucose 
output may be a key factor in hyperglycemia associated 
with diabetes . 
As precarious as our understanding of the homeostatic 
mechanisms concerning glucose is in the adult, it is still 
more tenuous in the case of the newborn. As was mentioned 
previously, the separation of the fetus from the placental 
source of nutrients results in a cascade of events, primary 
among them a change in the glucose production-utilization 
balance (24). Studies by Cahill (25) and others (26) have 
implicated glucagon as a necessary participant in the 
activation of glycogenolysis and gluconeogensis in the 
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newborn. The observation that glucagon and glucose bear 
an inverse relationship to one another in the newborn period 
(27) led some of the early studies to suggest that similar 
relationships as those seen in the adult occur routinely 
in the newborn period. Sperling et al (28) found that 
in normal newborns, glucagon secretion can be stimulated 
by alanine infusion. Other studies showed that infusion 
of alanine into the pregnant mother in labor produced 
higher levels of glucagon and glucose in the cord blood (29) 
when compared to similar results of women given saline 
infusions. 
Administration of alanine intravenously to newborn 
infants in one study produced a rise in glucose levels, 
but of small magnitude (30). In another study, results 
of alanine infusion were compared between groups of newborns 
and adults. Adults given an alanine infusion showed 
significant increases in serum alanine levels, but failed 
to show an increase in glucose. In contrast, marked in¬ 
creases in glucose (36 - 137 mg %) occurred in half of the 
normal and 1 small for gestational age infant at 6 hours 
of age. This increase was associated with similar eleva¬ 
tions of alanine, lactate, and pyruvate levels. By 36 
hours of age, all term newborns showed an increase in 
glucose of 12% in response to alanine infusion. Pyruvate 
and lactate levels rose 20-50% following the infusion (31). 
These results led the investigators to postulate that 
alanine is used for gluconeogenesis in the newborn, but 

that it may be incomplete, with some conversion to other 
products. 
Because of their tendency toward hypoglycemia (31), 
small for gestational age infants have also been studied 
with respect to alanine metabolism. Williams et al found 
that small for gestational age Infants had higher basal 
levels of alanine that control newborns (31) and that oral 
alanine feeding produced significant rises in glucagon and 
alanine levels in both groups. However, only the appropriate 
for gestational age infants showed consistent increases in 
glucose and insulin in response to alanine. In infants 
over 24 hours of age, alanine feedings had no effect in 
either group on levels of glucagon, insulin or glucose. 
The authors attributed these different responses to de¬ 
creased glycogen stored and/or inadequate gluconeogenic 
enzymes in the SGA infants. These studies were subsequently 
confirmed by another group using intravenous techniques 
of alanine administration (33). In addition to this work, 
a study by Haymond and coworkers examined glucose, lactate, 
amino acids, and several other substances in SGA infants. 
They found significant inverse correlations between glucose 
and lactate and glucose and alanine at two hours of age (32). 
Indeed, all potential gluconeogenic amino acids were found 
to be significantly elevated in these infants. 
To date there has been no reported attempt to ascertain 
the effect of alanine on infants of diabetic mothers. It is 
the purpose of the present study to investigate the effects 
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of an intravenous alanine load on infants of diabetic 
mothers. It is postulated that part of the mechanism 
involved in the neonatal hypoglycemia often' noticed in 
these infants may be related to an insensitivity or 
relative Insensitivity to substrate availability. Ad¬ 
ditionally, we have sought to establish temporal dif¬ 
ferences in IDM response to an alanine load which would 
correlate with either development of the neonatal regula¬ 
tory mechanisms or to the disappearance of maternal 
environmental antagonists. 
7 

MATERIALS AND METHODS 
A total of eight infants were included in the study- 
group. All study procedures had received prior approval 
by our hospital's Committee on Human Investigation. In¬ 
fants to be included in the study were selected on the 
basis of evidence of maternal diabetes. A mother was 
considered for the study if a) she demonstrated an ab¬ 
normal glucose tolerance test during her pregnancy, or 
b) she had a documented history of diabetes mellitus,. 
either insulin or diet controlled. These descriptions 
correspond to White’s classifications A and B (34). No 
infants of Class C-F diabetics were considered. There 
were no significant differences in birth weights or gesta 
tional ages between the two groups. All infants were 
between 38 and 40 weeks by dates. All infants in the 
study group were delivered vaginally, and all were in a 
vertex presentation at the time of birth. 
In addition to the screening process above, infants 
of Class A or gestational diabetic mothers were further 
evaluated after birth to assess their suitability for 
inclusion in the study. Only those infants demonstrating 
characteristics of IDM's were included in the study (35). 
Infants accepted for participation in the study were 
divided into two groups on a random basis, without regard 
to size, gestational age, or degree of maternal diabetes. 
The first group was studied at three hours of age. The 
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second group was studied at 12 hours of age. In the group 
studied at 12 hours of age, the infants were tested fol¬ 
lowing a four hour fast. The early group was studied prior 
to the first feeding. 
Infants included in the study group were observed 
closely for signs of hypoglycemia and other neonatal compli¬ 
cations. Any infant developing hypoglycemia (Dextrostix 
less than 45) was fed immediately and removed from the 
study group. Furthermore, any infant developing signs of 
neonatal distress (tachypnea, grunting, retractions, jaundice, 
etc.) was treated for that condition and removed from the 
study group. Infants to be studied at 12 hours of age were 
placed on a normal feeding schedule until four hours prior 
to the time of study. Any infant developing hypoglycemia 
during the four hour fast was removed from study. 
Prior to alanine infusion, blood was withdrawn from 
a heelstick or peripheral vein for baseline levels of alanine, 
insulin, glucose, and glucagon. Infants were then given'a 
bolus injection of 1-alanine (125 mg/kg) as a 10% solution. 
The solution was administered over a period of 3 minutes 
through a peripheral vein. The alanine solution was made 
up in our hospital pharmacy and underwent sterility and USP 
pyrogen testing prior to use. 
Following injection of 1-alanine, blood samples were 
withdrawn from a peripheral vein or heelstick at 15, 30, 
and 60 minutes. Blood to be analyzed for glucagon was im¬ 
mediately placed in chilled tubes containing EDTA (10.4 mg) 
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and Trasylol (1000 kalllkrein inhibitor units, FBA Pharma¬ 
ceuticals, New York). Samples to be analyzed for insulin 
were placed in chilled heparinized tubes (286 units USP 
heparin). Both sets of samples were refrigerated and centri¬ 
fuged, the plasma removed for analysis. Plasma was stored 
at -50 degrees C until assayed. Blood for- glucose was 
centrifuged immediately and the plasma removed. Blood to 
be analyzed for alanine was centrifuged, the plasma removed, 
and frozen at -50 degrees C until assayed. The total amount 
of blood removed from the infants did not exceed 15 ml over 
the course of the study. 
ASSAYS 
Glucagon and Insulin: Glucagon and insulin assays were per¬ 
formed for us by Dr. Philip Felig's laboratory in the section 
of Endocrinology and Metabolism, using a radioimmunoassay. 
The samples we submitted were processed along with regular 
clinical specimens and controlled using normal control 
procedures. Glucose: Glucose was measured in our hospital's 
clinical chemistry lab using their standard automated 
glucose-oxidase system. All samples were run in duplicate. 
ALANINE 
Alanine was measured in our lab using a microfluoro- 
metric technique modified after Lowry's method. 
Reaction sequence: 
GPT 
1) alanine + ketoglutarate - pyruvate + glutamate 
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LDH 
2) pyruvate + NADH + H —--lactate + DPN 
Materials: alpha ketoglutarate, alanine (grade III), 
reduced nicotinamide adenine dinucleotide (NADH), rabbit 
muscle lactic dehydrogenase (LDH, type III, crystalline in 
ammonium sulfate suspension), pig heart glutamic-pyruvic 
transaminase (GPT, suspension in 1.8 M ammonium sulfate 
solution), and tris (hydroxymethyl) aminomethane were all 
purchased from the Sigma Chemical Company. Potassium hydro¬ 
xide and perchloric acid were purchased from the Fisher 
Scientific Company. 
All glassware for this assay was cleaned following Lowry’s 
method, using a solution of concentrated nitric acid fol¬ 
lowed by rinsing in distilled water (high resistance greater 
than 1 meg ohm with low fluorescence background). The test 
tubes used to hold the intermediate solutions were standard 
10 x 75 mm glass test tubes. The fluorometric readings were 
made using quartz cuvettes cleaned in the above manner. 
Pteadings were made using a Perkin Elmer Hitachi flucrometer. 
All distilled water for this assay was purified as above and 
periodically tested for purity. 
Stock solutions of alanine, alpha keto glutarate (1.46 g/ 
100 ml distilled water), NADH (7 mg/ 10 ml distilled water), 
were made fresh immediately prior to the assay. Standard 
solutions of 3N perchloric acid, 25 mM Tris (pH 8.1), and 
3N potassium hydroxide were made up at the beginning of the 
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study and kept, refrigerated throughout the study. Solutions 
of LDH, and GPT were made up immediately prior to their 
addition to the reaction mixture. All solutions were 
pipetted using standard Corning glass pipettes. 
Methods: Samples obtained and stored as described 
previously were removed from the freezer and allowed to 
stand at room temperature until they had thawed completely. 
After the samples were mixed thoroughly, 100 microliters 
of serum was removed from each specimen and placed in a 
clean 10 x 75 mm test tube. The remainder of the serum 
was immediately returned to the freezer for later use. To 
the serum was added 350 microliters of chilled distilled 
water and 50 microliters of ice cold 3N perchloric acid. 
The tubes were then mixed gently on a Vortex mixer until 
thoroughly mixed, placed on ice, and allowed to settle for 
30 minutes. 
At the end- of this time, the specimens were placed in 
a centrifuge at 0 degrees C and spun at 500 g for an ad¬ 
ditional 20 minutes. 300 microliters of the supernatant 
obtained from these samples was removed and placed in 
labeled 10 x 75 mm test tubes. To this sample was added 
330 microliters of chilled distilled water and 29 microliters 
of ice cold 3N potassium hydroxide. This mixture was again 
mixed gently on a Vortex mixer and allowed to settle for 
30 minutes. At the end of this time, the pH of each tube 
was checked and adjusted to a final pH of between 6 and 7. 
This was done by adding small aliquots of the stock KOH 
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solution to the samples. The samples were then placed in 
the centrifuge and spun for an additional 20 minutes to 
settle the precipitate. The resulting supernatant was then 
removed for analysis. 
Clean cuvettes were check again for contaminants, 
following which, 100 microliters of supernatant was placed 
in each of the cuvettes. To this quantity was added 2.22 
ml of Tris solution, .03 ml NADH, 0.6 ml of alpha keto- 
glutarate. The cuvettes were then placed in the fluoro- 
meter and an initial reading was made. In those cuvettes 
containing alanine standards, the supernatant was replaced 
by an equal amount of alanine of known concentration. Each 
run also contained a blank. After the Initial reading had 
been made, 0.7 units of lactic dehydrogenase was added 
to the cuvettes at 5 second intervals. These were, in turn, 
mixed thoroughly and allowed to stand for 20 minutes at room 
temperature. The cuvettes were then placed in the fluoro- 
meter and readings were made in the same order as above, 
with 5 second intervals in between readings. 
After the readings had been recorded, .075 ml of GPT 
was added, in order, to each of the cuvettes, which were 
mixed thereafter. The samples were then placed in a water 
bath at 37 degrees C for 45 minutes. At the end of this 
period, the cuvettes were removed from the water and rinsed 
in distilled water several times and dried completely. They 
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were allowed to stand, at room temperature for an additional 
25 minutes, at the end of which time, a final reading was 
made of each cuvette in the same order. 
Fluorometric readings were translated from a standard 
curve constructed earlier and standard concentrations of 
alanine were compared for accuracy with each run. Samples 
were run in batches and in duplicate. Test results from 
this method were checked prior to the assay of actual 
samples with the results obtained using an amino acid 
analyzer in Dr. P. Felig's laboratory. A good correlation 
was obtained between these data. Dr. Felig's results, and 
the known concentrations of the test samples. 
STATISTICS 
All statistics were analyzed for paired, grouped, and 
student analysis where appropriate. All data was compiled 
and analyzed on a Hewlett-Packard model 9830 A computer 
programmed for such calculations. 

RESULTS 
The study group was divided into early (3 hours) 
and late (12 hours) subgroups. All infants studied were 
either offspring of Class A or Class B diabetic mothers. 
There were no statistically significant differences 
between baseline values for any of the substances studied. 
GLUCOSE 
Baseline glucose values were obtained from cord samples 
in the 3 hour group and from heelstick determination in the 
12 hour group. The early group showed a median cord blood 
glucose of 119-3 ± 37 mg/ml (mean ± S.E.M.). This corres¬ 
ponds to data obtained by King and others (18) who reported 
a cord value of 129.0 ± 12.0 mg/100 ml for infants of 
diabetic mothers. The baseline value for the later group 
was 48.4 ± 5-9 mg/100 ml (mean ± S.E.M.). This value also 
correlates with available data for IDM's at this age. 
The blood glucose levels for the early group showed 
no significant rise in response to the intravenous alanine 
infusion. Although blood glucose levels were not known at 
the exact time of infusion, there was no significant rise 
in plasma glucose levels from 15 minutes after infusion 
(36 ± 8.0 mg/100 ml) to the completion of the study at 1 hour 
after infusion (37.6 ± 9-4 mg/100 ml) (p greater than .05). 
These results are similar to those obtained by Williams et al 
(29) in normal infants given 89 mg/kg boluses of 1-alanine. 

They also agree with the results obtained in normal infants 
given 125 mg/kg infusions in Mestyan’s work (33). 
ALANINE 
Significant elevations in plasma alanine levels were 
noted following infusion in both early and late groups. In 
the 3 hour group, the initial concentration was 277.2 ± 21.9 
micro M/L. This compares with normal adult levels and normal 
newborn levels of 254 ± 22 micro M/L as reported by Raymond 
et al (32). The 12 hour group had baseline levels of 383.9 ± 
51.2 micro M/L. This compared to a level of 1033 ± 133 micro 
M/L noted by De Lamater et al (29) in normal newborns at 
12 hours of age. 
The 3 hour group showed a significant (p less than .005) 
rise in blood alanine levels at 15 minutes post infusion. 
A peak of 1117*3 ± 452 micro M/L was reached at 15 minutes 
with a reduction to 634.3 - 97 micro M/L at the end of the 
test (1 hour). There was not a significant difference 
between the mean baseline concentration and the final con¬ 
centration . 
The 12 hour group showed a similar rise in alanine levels 
reaching a mean peak of 1912 ± 184 micro M/L at 30 minutes. 
This represented a mean increase of 1528 ± 150 micro M/L. 
This peak value fell to a mean of 986.1 ± 79 micro M/L at 
the end of the study, a significant (p less than .001) 
elevation above the starting concentration. 
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GLUCAGON 
Although elevations of serum glucagon levels were 
noted in both the early and late groups, the rise was not 
significant in the 12 hour group. The 3 hour group had 
mean baseline (cord) glucagon levels of 233.1 - 100 pg/ml. 
The mean baseline value for the 12 hour group was 155 - 
33 pg/ml. These values correlate well with those observed 
in normal (29, 31) and small for gestational age infants (33). 
INSULIN 
Insulin values fell over the course of the study in 
both groups from the initial concentrations to those ob¬ 
tained at the end (1 hour later). Unfortunately, due to 
large standard errors, these differences were not statistically 
significant. 
In the early group, the mean baseline insulin con¬ 
centration was 151-5 ± 128.0 micro U/ml. This concentration 
decreased to 30.67 ± 2.33 micro U/ml by the end of the study. 
In the later group, the mean baseline concentration was 66.6 ± 
21.4 micro U/ml, falling to a final concentration of 22.2 ± 
4.7 micro U/ml by the end of the period. Both sets of values 
are appreciably higher than those obtained in normal and 
small for gestational age infants (31), and while the differ¬ 
ence approches but does not attain statistical significance, 
the 12 hour group had a lower mean baseline insulin concentration 
(mean less than half) than the 3 hour group. 
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DISCUSSION 
In order to adequately interpret the data presented 
and to make some conclusions about the physiology involved, 
it is worth reviewing some of the known interactions between 
alanine and the major glucogenic hormones. 
The primacy of alanine in the glucogenic pathway has 
been alluded to earlier. After the work of Van Slyke and 
Meyer, London and his co-workers measured the arterio¬ 
venous differences in levels of aminos acids in human 
forearms. They found a uniformly negative difference in the 
levels of 11 of 17 studied amino acids. Of these amino acids, 
alanine was released from these tissues in the highest con¬ 
centration, in some instances accounting for 30% of the 
amino acid content (37). This work has subsequently been 
supported by the findings of other investigators working with 
subjects in different states of fasting (38, 39, 20). 
The significance of the discovery that alanine is released 
in these higher concentrations is magnified by the fact that 
alanine comprises no more than 10% of the total amino acid 
content in skeletal and cardiac muscle (20). This predominance 
of alanine as the major source of nitrogen in the intracellular 
pool has led investigators to speculate that there must be 
another source of derived alanine in these tissues. Felig has 
suggested that the source of alanine is pyruvate (38), which 
is transaminated in the muscle to create alanine. This 
observation is supported by the direct correlation between 
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levels of circulating alanine and circulating pyruvate (40), 
a relationship which is not found in the other circulating 
amino acids of man. Other conditions of hyperpyruvatemia such 
as muscular exercise (40) and inborn enzymatic defects (20,41) 
also demonstrate a commensurate hyperalaninemia. The pos¬ 
sibility exists that the alanine which is released is not 
synthesized solely from pyruvate, but that the alanine might 
in fact be formed from the breakdown of other types of amino 
acids which are then converted to alanine in the muscle. 
This hypothesis has the advantage of explaining a recycling 
of various carbon skeletons back into the glycolytic pathway. 
Further evidence in support of this theory is offered by the 
observation that many tissues use alanine as a means of 
disposing of nitrogen from other amino acids (42). 
The liver also appears to be important for the recycling 
of alanine in the glycolytic cycle. Studies on hepatic 
perfusion in dogs and man have shown that alanine is prefer¬ 
entially extracted from the blood stream in much higher levels 
than other amino acids (43, 44, 45). As was seen in the 
pattern of amino acid release from muscle, splanchnic uptake 
of amino acids shows alanine consumption to be the highest, 
accounting for nearly 50% of the total amount of amino acid 
extracted from the blood. 
Perhaps one of the last links in this pathway involved 
establishing that the alanine was in fact incorporated in the 
glucose molecule. This was done in postabsorptive man and 
19 

showed that alanine was incorporated into glucose, with 
the optimal recovery of labeled product at between 30 and 
60 minutes after infusion (20, 46). Additionally, studies in 
which alanine was given via catheter to a perfused liver 
have shown alanine induced the highest rise in glucose of 
any amino acid used (47). 
This pathway from skeletal muscle to liver and back 
to skeletal muscle is subject to the usual regulatory 
control mechanisms which have long been known to control 
glucose homeostasis. Glucagon is known to be a stimulant 
to increased gluconeogenesis (48). One would expect, there¬ 
fore, that glucagon would cause an increased production of 
glucose from alanine through gluconeogenesis. And, in 
fact, studies using labeled alanine have shown that in¬ 
corporation into glucose increased in the presence of glucagon 
(49, 50). This stimulation of glucagon secretion has been 
shown to be inhibited by secretin in studies of dogs (51). 
The mechanism, while not precisely known, does not appear to 
involve the usual feedback by insulin. In addition, in 
the presence of glucagon, the liver shows a preferential 
uptake of alanine. This increase in uptake is most probably 
due to conversion of alanine to glucose rather than to increased 
cellular uptake per se (52). Studies in intact human subjects 
have demonstrated similar findings to those quoted above for 
liver perfusion tests (53). In addition, subjects with acute 
hepatitis and abnormal hepatic glucogeogenic mechanisms show 
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a decreased response to glucagon with respect to alanine (5^). 
Glucagon also seems to be active at the other end of the 
cycle, causing an increase in extrahepatic metabolism of 
alanine as well (20). 
The relationship between alanine and glucagon appears 
to work both ways. That is, studies have shown that increase 
alanine results in a concomittant increase in glucagon (55). 
This effect is essentially abolished by states in which 
there is increased glucose available, such as obesity (20), 
but is enhanced in conditions in which glucose availability 
is decreased, such as fasting. A direct linear relationship 
between alanine and glucose and glucagon has been demonstrated 
(56). 
The relationship between insulin and amino acid levels 
has been known for some time (57). Study of various models 
has led to the elaboration of the scheme of insulin effect 
which seems to be enhancement of amino acid uptake by muscles 
and subsequent incorporation into muscle protein (20). These 
early, yet non-specific studies suggested to some investi¬ 
gators that the effect of insulin was via hypoaminoacidemia 
(58). Unfortunately, however, subsequent studies of the 
effects of insulin on individual amino acids has shown this 
is not to be a likely mechanism. In studies of specific amino 
acids, both in man and animals, the reduction in concentration 
following administration of exogenous insulin or stimulation 
of endogenous insulin via glucose administration is related to 
branched chain amino acids primarily (valine, leucine, and 
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isoleucine) with alanine being the only amino acid which 
does not show a consistent decline following these tests 
(20). In fact, some studies have shown a rise in alanine 
concentration following insulin increase (20). It seems 
likely from subsequent studies that insulin causes an 
increase in peripheral alanine formation. This increase 
is most likely due to the transport of glucose into the 
cells under the influence of insulin. The flux of glucose 
results in a surplus of pyruvate which may be subsequently 
transaminated to form glucose (alanine) (21, 59). Therefore, 
the observed levels of alanine following insulin are the 
results of a counterbalance of increased production and 
increased absorption. If, therefore, insulin does not 
cause a decrease in available alanine, and if, in fact, 
alanine is the source of glucose In the gluconeogenic 
pathways, the control of gluconeogenesis from alanine by 
insulin must reside in the hepatic portion of the cycle. 
In studies on intact human subject, Felig and Wahren 
(60) found that a hyperinsulinemic state, with the subse¬ 
quent fall in hepatic glucose output, caused a decrease 
in hepatic uptake of alanine of 30-60$. Other amino acids 
were not similarly affected. These studies in intact sub¬ 
jects are supported by other work with perfused livers which 
has demonstrated that the amount of labeled alanine in glucose 
produced insulin. Thus the liver seems to differ from other 
tissue in its response to insulin. Unlike the protein in¬ 
corporation seen in muscle in response to insulin, the liver 
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seems to be unaffected by insulin with respect to protein 
incorporation (20). 
In studies of perfused rat livers, Sladek and Snarr 
showed that there is a significant inhibition of gluconeo- 
genesis in the presence of insulin. This inhibition could 
be expressed in terms of a linear equation (Rate of glucone- 
ogenesis (micro m/hr/g wet wt) = 15.93 - 0.0084 (Insulin, 
micro U/ml)). This inhibition was felt to be a direct in¬ 
hibition of gluconeogenesis rather than an increase in con¬ 
version of glycogen, since previous studies by Jefferson 
et al using labeled glucose had shown that insulin inhibits 
gluconeogenesis without increasing labeling of glycogen (6l). 
The relationship between alanine and insulin, like the 
one between alanine and glucagon, seems to work both ways. 
The relationship between alanine and insulin seems to differ 
in some respects from a simple glucose-insulin stimulation. 
In studies of dogs which had been fasted for 5 days, Buckman 
et al found that while glucogenic insulin secretion was 
markedly reduced in these animals, the insulin response to 
alanine was not affected. While it is possible that the 
alanine is acting through glucagon stimulation (leading to 
insulin secretion) the authors point out that arginine causes 
a rise in glucagon levels without a concurrent insulin increase 
(62). Thus, the precise mechanism of alanine induction of in¬ 
sulin secretion is still unclear. 
The sequence of biological events which occur following 
delivery of an infant has been fairly well established. 
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Metabolically, the clamping of the umbilical cord represents 
a marked diminution in the infant's supply of glucose. 
This results in increased pancreatic secretion of glucagon. 
Shortly thereafter, adenylcyclase is activated in hepatic 
and adipose tissue causing a commensurate increase in gly- 
cogenolysis and lipolysis. Shortly thereafter, the enzymes 
phophoenolpyruvate kinase, glucose-6-phosphatase and trans¬ 
aminases including tyrosine transaminase (TAT) become 
activated to increase the rate of gluconeogenesis. The exact 
order of these events, particularly glycogenolysis vs glu¬ 
coneogenesis is unknown in man. In studies on the rat, 
gluconeogenesis appears to preceed glycogenolysis. 
Although this classic description of events has been 
accepted for some time, there has been some discussion lately 
concerning the extent and nature of the glycemic response to 
alanine in man. Hahn, in a NEJM editorial, considered that 
response seen in infants given oral alanine loads. He pointed 
out that the infant's caloric requirements during the course 
of the study in question far exceed the amount provided by 
the alanine given. Since a glycemic response was noted, 
however, he suggests that this must be a function of increased 
glycogenolysis and gluconeognesis brought about by elevated 
glucagon levels, with the implication that alanine alone could 
not account for the glucose rise on a mole for mole basis (63). 
There is evidence to suggest that the role of alanine in 
stimulating glucose production can be that of an inducer rather 
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than of substrate. In an elegant study by Friedrichs and 
Schoner, the effects of alanine levels on renal gluconeo- 
genesis were investigated. Unlike its function in liver 
tissue, alanine is a very poor substrate for gluconeogenesis 
in the kidney. In addition, the renal cortex has a very low 
level of glycogen, so glycogenolysis would interfere rela¬ 
tively little. Using this model, Friedrichs found that 
alanine acted to produce a glucose rise which was independent 
of substrate concentration (catalytic). From their observa¬ 
tions, they concluded that alanine was acting to inhibit 
pyruvate kinase (64). Considering data from other studies, 
the authors concluded that a certain amount of pyruvate 
(cycling) occurs in the liver under the influence of pyruvate 
kinase. In order to achieve effective glucose production, 
pyruvate kinase must be inhibited. Alanine appears to do 
just that. 
However, data from other sources indicates that the 
glycemic-response can, in some case, be accounted for on a 
mole-for-mole basis as well. From data with rat liver slices, 
it was estimated that a threefold increase In plasma alanine 
concentration could result In a 172% increase in the rate 
of gluconeogenesis (65). Additional data accumulated from 
rat liver perfusion studies has confirmed that seen In the 
liver slice studies (6l). The authors of the latter study 
were able to derive a linear relationship between the rate 
of gluconeogenesis and alanine concentration in the range of 
.45-4.0 mM. (Gluconeogenesis (micro m/hr/g liver) = 0.6l + 
5.53 (Alanine, mM). 
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In light of these two conflicting theories, one is 
prompted to suppose that the infants studied in the series 
reviewed by Hahn were in some sort of homeostatic balance 
prior to the alanine administration. Though it is unclear 
what mechanisms were supplying these infants with glucose 
at the time, the chances are that it was combined lipolysis 
and glycogenolysis. The alanine which was administered, 
therefore, was not needed to provide the infants with all 
the calories they needed to maintain normoglycemia, and 
they were able to show a glycemic response. 
In the present study, two different responses to 
intravenous alanine administration were obtained. In the 
early group (3 hours) there was no significant glycemic 
response to alanine (in fact, glucose levels continued 
to drop in one infant). In the later group (12 hours) 
there was a marked glycemic response to the alanine. In¬ 
terpreting the data from the early group is difficult, 
largely because of the small sample size. The reason for 
the small size is twofold. First, it was technically more 
difficult to perform the study on the younger Infants. 
Besides the logistics involved in preparing the necessary 
equipment and obtaining consent within 3 hours or so, these 
infants proved to be more edematous, and it was harder to 
obtain blood in the amounts needed. Secondly, the sample 
size was limited by us for ethical reasons. After the first 
few infants were studied, it seemed quite likely that there 
would be no significant glycemic response to the alanine. 
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In fact, some infants entered the study but became hypo¬ 
glycemic and had to be fed prior to completion of the study. 
For this reason, it was decided to change the time of 
study to 12 hours of age. These limitations do not in¬ 
validate the data obtained. However, it is not possible 
to rely as heavily on it as one would like. 
What can be determined from the early group are a 
few trends. First, the failure to show a glycemic response 
to alane. Second, a relative rise in glucagon levels from 
baseline to peak. Third, a similar peak in alanine levels 
which was a significant increase from baseline levels. And, 
finally, a hyperinsulinemic state which moderated over the 
course of observation. 
The simplest way to interpret these data is to explain 
them on the basis of hyperinsulinemia. It could be suggested 
that the abundance of insulin, presumably of maternal origin, 
blunted the infant’s response to alanine. One would postulate 
that the pancreas responded as expected In these infants with 
an increase in glucagon, but that a) the liver did not extract 
the Infused alanine in the presence of a relative hyper¬ 
insulinemia, b) the glucagon failed to produce the expected 
gluconeogenic or glycogenolytic response in the liver. 
Of these, the first seems to be the most likely. As 
was mentioned previously, in work with perfused livers, it 
has been shown that insulin excess decreases the rate of 
hepatic alanine extraction (66). One would expect in such a 
case to see a rapid rise in alanine levels after infusion. 
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reaching a relatively high peak concentration, followed by 
a gradual fall off or plateau. Although the data is 
scanty here, this is, in fact, what is seen. The peak 
levels are not significantly different from those of the 
later group, but there is a more gradual fall of alanine 
levels in these infants than that seen in the later group. 
The second possibility, that is, a failure of hepatic 
function, might also be considered. It is known that 
cyclic AMP or glucagon, particularly in combination with 
adrenal steroids, can bring about a 10 fold increase in 
the activity in the gluconeogenic enzymes PEPK and TAT 
as early as 20 weeks of gestation (67). One would assume, 
therefore, that term infants, as studied here, would be 
capable of converting substrate into glucose. The ele¬ 
vated levels of adrenal steroids found in IDM’s (3^) 
would lead one to suspect an acceleration in this 
pathway in fact. 
Another possible cause for impaired gluconeogenesis, 
or more importantly, glycogenolysis, is depletion of hepatic 
reserves. In their studies on neonatal hypoglycemia, 
Cornblath et al concluded that the decreased response to 
glucagon administration in these infants prior to the 
development of symptoms indicated diminished hepatic glycogen 
reserves. After administration of parenteral glucose and 
steroids or ACTH, a normal response to glucagon was obtained. 
(68) Hahn, in his editorial, suggests that a condition of 
maximal glucose production might exist in some newborns 
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immediately after delivery. Presumably this increased rate 
might be related to an elevated "glucostat" set during a 
hyperglycemic pregnancy. If this were the case, admini¬ 
stration of alanine, which would normally induce the 
production of glucose would not have any further effect 
on serum glucose levels. In infants in whom glucose 
production from glycogenolysis was not maximal, the alanine 
would presumably act in its usual way and a glycemic response 
would occur (63). Such a theory, however, must explain 
the observations of Williams et al that infants who show 
a glycemic response to alanine on the first day do not 
show such a response on the second day. The authors explain 
this discrepancy on the basis of a higher glucose level, 
which acts in some way to shut off a further glycemic 
response. 
The second (later) group of infants studied confounds 
the results from the earlier group in many ways. As men¬ 
tioned previously, these newborns showed a significant 
glycemic response to the infused alanine during the course 
of the study. The rise in glucose was associated with a 
rise (although not statistically significant) in glucagon, 
which began shortly after injection of the alanine. Alanine 
levels in these infants rose to higher levels than those 
seen in the earlier group, and the final levels of alanine 
were elevated above the initial concentrations as were 
those seen earlier. Insulin levels in these infants were 
elevated above normal, but not as much as were those in 
the earlier infants. 
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One would like to attribute the difference in. responses 
to the lower insulin levels in this group. One could 
postulate in that event that the first group failed to 
respond merely because of a hyperinsulinemia. However, 
as appealing as this theory is, there are several in¬ 
consistencies with it. 
First, the insulin levels in the later group are still 
above normal, and, although they are lower than the early 
group, the difference is not great. In their studies 
with perfused rat livers, Sladek and Snarr found that a 
significant inhibition of gluconeogenesis could be produced 
by as little insulin as 10 micro U/ml rising to a maximum 
inhibition in the range of 500 micro U/ml (6l). 
Secondly, were the differences due to hyperinsulinemia, 
one might expect that the peak alanine levels seen in 
the second group would be lower than those seen in the 
early group. Presumably, with less insulin to interfere 
a higher rate of gluconeogenesis would exist, and the 
alanine would be used more rapidly. The final concentra¬ 
tion (60 minutes) might be expected to be lower than in 
the early group as well, since presumably more alanine 
would then have been converted to glucose. As can be 
seen from the data, this is not the case. 
A more intriguing approach concern glycogen metabolism 
in these infants. It is well known that in the immediate 
post partum period, the infant mobilizes glycogen stores, 
at a rapid rate. In addition, fat in subcutaneous tissue 
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is also used. This increase in glycogenolysis is known 
to start prior to delivery and continue at a high rate 
through the first few hours of life, until exogenous 
sources become available. IDM’s have been found to have 
higher glycogen stores at birth as well as increased rates 
of glycerol release from these tissues after birth (69). 
It is felt that the neonate uses glycogen stores prefer¬ 
entially, reducing the amount of FFA which is released 
into the circulation (70). A fall in the levels of ATP 
in these tissues is also noted during this time (69). 
From these observations, one would expect that the 
infants in the first group were experiencing a high, and 
perhaps maximal glycogen turnover at the time of the 
study. If -alanine were acting through increased glucagon 
and a resultant glycogenolysis, one would expect to see 
little if any response to the infusion of alanine, since 
rates were maximal at the outset. In the later group, 
which had been fed prior to the study, one might expect to 
find a lower rate of glycogenolysis at the beginning of 
the study. They would be able to increase the rate, 
and show a glycemic response. 
Although earlier studies have shown that glycogen 
stores become depleted with time following delivery (71) 
in the present study, the infants in the later group were 
fed prior to the start of the alanine infusion. One might 
suggest that glycogen stores were either replenished or in 
the process of being replenished and were, therefore, responsive 
to alanine-induced, glucagon-mediated glycogenolysis. One 
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would not have to invoke increased gluconeogenesis to 
account for this response, thus circumventing the problems 
associated with the hyperinsulinemia which still existed 
at the later time. Nor would one expect to see significant 
changes in the alanine-disappearance rate, since the alanine 
would not be used up in the glycemic response. All of 
this presupposes that the infant’s glycogen stores were 
sufficient at 12 hours of age after feeding to support the 
required substrate for the glycemic response. We have no 
way of knowing that this is the case, but we do know that 
insulin increases the rate of glycogen formation following 
feeding (69). Thus, one might postulate that the same 
condition which resulted in a failure of the early group 
to respond to alanine infusion (hyperinsulinemia) brought 
about the increased glycogen stores which allowed the 
later group to respond. 
The hypothesis proposed above conflicts somewhat with 
observations of Pildes et al (72). They found that infants 
primed with dextrose prior to glucagon infusion did not 
respond to glucagon as did normal infants. They speculated 
that this might be due to antagonizing effects of glucagon 
and insulin in the liver. Were this the case in the present 
study, one would expect much different results than those 
obtained. However, there are significant differences 
between that study and this. In the Pildes study, the infants 
who did not respond were primed with intravenous dextrose 
as a 10$ solution. This infusion was not stopped until 30 
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minutes prior to the study. Their controls, however, were 
fasted for 3-6 hours prior to study, depending on the age 
of the infant. In our study, the older group was fed orally 
at intervals of 3 hours, which is our usual feeding regimen 
for such infants. These infants were then fasted for four 
hours prior to study. In this respect, therefore, the 
older infants in our study were more similar to the control 
infants in the Pildes study, which did respond to glucagon 
(72). 
Evidence accumulated from the present study also stands 
in opposition to that presented by Bloom and Johnston (73)- 
They studied fifteen infants of diabetic mothers and 
compared them with normal infants and small for dates 
infants. They showed that at two hours of age, infants of 
diabetic mothers had a significantly smaller rise in 
glucagon levels than did the other groups. Although our 
early group was very small, results obtained from them 
at 3 hours showed them to have a greater increase in 
glucagon levels than the later group when challenged with 
alanine. Infants in the later group showed glucagon ele¬ 
vations which were greater than those observed in Bloom’s 
normal controls. These discrepancies can be explained in 
terms of a biofeedback system. The early group in our study 
seemed to produce glucagon adequately in response to alanine, 
a known glucagon stimulant. However, if one supposes that 
these infants, as previously suggested, were unable to 
a) clear alanine via gluconeogenesis or b) produce glucose, 
and thereby "shut off" glucagon production via glycogenolysis, 
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one would expect to see the high levels obtained in our 
study. One should also point out that all of the infants 
studied in Bloom’s group were infants of Class B or worse 
diabetics. One would suppose that insulin levels in these 
infants were significantly higher than those obtained 
from our study of primarily Class A diabetics. Since the 
number of infants studied in our protocol was very small, 
one is reluctant to ascribe too much significance to this 
difference in data. 
One might argue that the difference noted in the two 
groups of infants demonstrates a relative phosphoenolpyruvate 
carboxykinase deficiency early in life with a subsequent 
appearance by 12 hours of age which enables the older infants 
to respond. It has been shown in experiments with rats (20) 
that the level of PEP carboxykinase increases dramatically 
from the time of birth until it reaches a plateau at about 
8 days of age. Although no such data exists for man, it 
could be argued that a similar process at work here pre¬ 
vented the 3 hour group from responding, while the later 
group did. 
Several points mitigate against this explanation. First, 
we have evidence from studies of normal infants (31) that 
they are capable of responding to alanine infusion at an 
early age. Admittedly, however, many-of the infants in that 
study did not respond until 36 hours. Secondly, the alanine 
disappearance curves, while not a precise measure of 
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utilization, would seem to indicate that there was, if 
anything, more substrate utilization in the 3 hour group. 
Finally, as pointed out earlier, the magnitude of the gly- 
cemic response seen exceeds that which can be accounted for 
by direct conversion of alanine to glucose, an indication 
that gluconeogenesis alone is not responsible for the gly- 
cemic response. 
All of this notwithstanding, our data does not rule out 
the possibility of PEP carboxykinase deficiency in these 
infants. The fact that such a state seems to be more or less 
universal in newborns suggests to us that there is more in¬ 
volved in the hypoglycemia of diabetic infants. Further 
and more specific studies must be undertaken to determine 
this more precise information. 
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SPECULATION 
One is now left with the difficult problem of putting 
all of these assorted bits and pieces of information into 
some sort of unified concept. We would not pretend to 
be able to elaborate a complete pathway on the basis of 
our current data; however, it is tempting to speculate as 
to the mechanisms involved. In that spirit, one can 
construct the following picture. 
Alanine’s mode of action is via two major pathways: 
gluconeogenic and glycogenolytic. The gluconeogenic pathway 
may be subdivided into substrate mode and catalyst mode 
action. The substrate pathway operated through the con¬ 
version of alanine into glucose using the normal gluconeo¬ 
genic pathways. The catalytic process seems to work through 
an inhibition of pyruvate kinase. The inhibition of 
pyruvate kinase causes an increase in glucose production 
through a re-channeling of phosphoenolpyruvate which pro¬ 
ceeds up the gluconeogenic pathway to glucose. This 
inhibition of pyruvate kinase was overcome by fructose- 
1, 6-diphosphate in studies on the rat kidney (21). There 
is no evidence as yet what the effects of either insulin 
or glucagon are on this process. However, the authors 
of that study indicated that the pathway might be different 
from the known process which involves cyclic AMP. 
The substrate mode of action seems to relate to levels 
of both glucagon and insulin. Although it has been suggested 
that insulin has a blocking action on gluconeogenesis 
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independent from glucagon levels, (6l) there is more 
evidence to suggest that the rate of gluconeogenesis is 
a function of the molar ratios of glucagon to insulin (72). 
Thus one might expect that in patients such IDM's, the 
high insulin level could be overcome by a sufficiently 
high glucagon level, and that the insulin level by itself 
is less important in determining whether or not gluconeogene¬ 
sis is to proceed. 
The glycogenolytic mechanisms referred to are probably 
mediated by glucagon. Alanine is known to be a potent 
stimulus to glucagon secretion (76). In the dog, this 
stimulation can be effectively blocked by the administration 
of secretin (75). Glucagon may be acting through stimulation 
of cAMP, activating phosphorylase, and deactivating glucagon 
synthetase, . Glucagon stimulated glycogenolysis may be 
blocked by insulin, which is also stimulated by alanine. 
It has been suggested that insulin opposes the action of 
glucagon in this regard by means of a second messenger, 
opposing the action of cAMP (72). The levels of cAMP- 
stimulated phosphorylase and cAMP-inhibited glycogen syn¬ 
thetase may be related to environmental factors, and may 
constitute a "glucostat" as postulated by one author. One 
might suppose that membrane phenomena might alter the sensi¬ 
tivity of this sytem to various levels of glucagon in order 
to maintain homeostasis. Insulin has also been shown to 
stimulate glycogen synthetase. 
Glucose produced from either or both of these systems 
is known to stimulate insulin production. It has also been 
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shown that this stimulation is blocked by starvation, 
whereas alanine stimulation of insulin is not (62). Glucose 
is metabolized to form pyruvate in some instances, and 
pyruvate may then be converted into alanine in the muscle 
for re-entry into this system. Glucose can also act to 
interfere with the alanine-stimulated secretion of glucagon. 
In light of these facts and the evidence presented 
in the body of this paper, one can postulate that in the 
three hour group, insulin levels were such that the 
alanine-mediated glucagon secretion was not sufficient to 
overcome the effects of a relative hyperinsulinemia and 
cause a resulting gluconeogenesis. However, in light of 
the concentration of alanine infused and the demands of a 
newborn infant at this stage, this must be considered a 
less likely explanation. As Hahn points out in a criticism 
of a similar study (63), the amount of alanine given in this 
study cannot explain a rise in blood glucose if suggested 
on a mole-for-mole basis. It is possible, however, that 
the effect of alanine was catalytic in nature as mentioned 
earlier. This would pre-suppose, however, that there was 
an abundance of other substrate present at the time from 
which to make glucose. Given the period of fasting after 
birth and the demands of a stressful environment, it is 
unlikely that there is such a surplus present. 
Rather, it seems more likely that glycogenolysis is 
proceeding at a rapid rate at this time the baby’s life. 
With production of peripheral glucose proceeding at near 
maximal rates without any stimulus, it is unlikely that 
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the presence of alanine could cause a detectable rise 
in peripheral glucose. One would imagine that any extra 
glucose production from such a stimulus would be un¬ 
detectable by our methods. 
By 12 hours of age, the insulin levels had moderated 
somewhat. In addition, since the infants had been fed, 
one can postulate that glycogen was being formed from 
exogenous glucose, and that glycogenolysis was being 
inhibited by decreased glucagon levels and insulin in¬ 
hibition of cAMP. Following administration of alanine 
to this group, inhibition of pyruvate kinase can be postu¬ 
lated, as well as stimulation of glucagon. In the presence 
of lower levels of Insulin, the glucagon secretion was 
sufficient to make the glucagoneogenic system receptive 
to substrate. 
However, in light of what has been previously stated 
concerning the amount of alanine given, its inadequacy 
as substrate, and the unlikely presence of excess substrate 
of other kinds following a four hour fast, we must favor 
a glycogenolytic mechanism to explain the rise in glucose 
seen in the later group of infants. Perhaps following feeding 
partially repleted glycogen stores were being used at sub- 
maximal rates. Following the infusion of the alanine, a 
rise in glucagon levels occurred. This added glucagon 
stimulation resulted in a return to maximal glycogenolysis and 
a resultant glycemic response. 
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Table 1 summarizes the results of serial glucose determin¬ 
ations at 3 and 12 hours of age. These data are pre¬ 
sented graphically as absolute (Figure 1) and increment¬ 
al values (Figure 2). As can be seen, there is no sig¬ 
nificant increase in glucose values after infusion in the 
3 hour group while the 12 hour group showed a marked 
elevation. 

Table 1 
GLUCOSE (mg/dl) 
3 HOURS (Absolute) 
TIME MEAN STD. DEV. STD. ERR 
0 119.33333 64.66323 37.33333 
15 36.00000 13.89244 8.02081 
30 34.66667 19.85783 11.46492 
60 37.66667 16.28906 9.40449 
3 HOURS (Change) 
TIME MEAN STD. DEV. STD. ERR 
0 0.00000 0.00000 0.00000 
15 -83.33333 76.56588 44.20533 
30 -84.66667 82.52474 47.64568 
60 -81.66667 79.05273 45.64111 
12 HOURS (Absolute) 
TIME MEAN STD. DEV. STD. ERR 
0 48.82000 13.24092 5.92152 
15 54.04000 16.39857 7.33366 
30 61.72000 13.33480 5.96351 
60 70.84000 16.98906 7.59774 
12 HOURS (Change) 
TIME MEAN STD. DEV. STD. ERR 
0 0.86000 1.92303 0.86000 
15 6.08000 3.52945 1.57842 
30 12.90000 5.98916 2.67843 
60 22.02000 16.05372 7.17944 
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Table 2 summarizes the data from alanine determinations 
during the study. Both groups show significant increases 
(Figures 3 and 4) in alanine levels within 15 minutes 
after infusion. Although the 12 hour group showed high¬ 
er serum levels after infusion, the difference was not 
significant. 
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Table 2 
ALANINE ( |iM/ L ) 
3 HOURS (Absolute) 
TIME MEAN STD. DEV 
0 277.16667 38.00110 
15 1117.33333 783.17963 
30 1060.50000 67.86199 
60 634.33333 169.10450 
3 HOURS (Change) 
TIME MEAN STD. DEV 
0 0.00000 0.00000 
15 840.16667 764.25165 
30 783.33333 89.78354 
60 357.16667 149.38736 
12 HOURS (Absolute) 
TIME MEAN STD. DEV. 
0 383.90000 114.47401 
15 1792.30000 356.72496 
30 1912.60000 412.09501 
60 986.10000 177.40011 
12 HOURS (Change) 
TIME MEAN STD. DEV 
0 0.00000 0.00000 
15 1408.40000 442.16377 
30 1528.70000 336.68710 
60 602.20000 103.00279 
STD. ERR. 
21.93994 
452.16897 
39.18014 
97.63253 
STD. ERR. 
0.00000 
441.24090 
51.83655 
86.24883 
STD. ERR. 
51.19434 
159.53225 
184.29449 
79.33574 
STD. ERR. 
0.00000 
197.74165 
150.57105 
46.06425 
46 

A
LA
N
IN
E 
(fi
M
/L
) 
ALANINE (Absolute) 
47 

1600 
1400 
1200 
1000 
800 
600 
400 
200 
0 
Figure 4 
15 30 45 60 
TIME (minutes after infusion) 
.ANINE (Change) 
48 

Table 3 shows the glucagon values and increments above 
baseline following infusion. As can be seen from 
the graphs (Figures 5 and 6) the alanine produced a 
significant glucagon response in both groups of 
infants. The 3 hour group continues to increase 
throughout the study while the 12 hour group shows 
a decrease after 30 minutes. 

Table 3 
GLUCAGON ( pg/ml ) 
3 HOURS (Absolute) 
TIME MEAN STD. DEV. STD. ERR. 
0 233.13333 174.72107 100.87526 
15 521.66667 105.39608 60.85045 
30 441.66667 140.56434 81.15486 
60 651.66667 359.03807 207.29072 
3 HOURS (Change) 
TIME MEAN STD. DEV. STDo ERR. 
0 0.00000 0.00000 0.00000 
15 288.53333 174.94414 101.00405 
30 208.53333 77.83607 44.93867 
60 418.53333 211.89963 122.34031 
12 HOURS (Absolute) 
TIME MEAN STD. DEV. STD. ERR 
0 155.60000 75.96825 33.97403 
15 268.00000 222.48174 99.49686 
30 332.30000 380.18689 170.02475 
60 226.80000 107.80747 48.21297 
12 HOURS (Change) 
TIME MEAN STD. DEV. STD. ERR 
0 0.00000 0.00000 0.00000 
15 112.40000 259.34061 115.98064 
30 176.70000 398.10781 178,03922 
60 71.20000 115.10897 51.47830 
50 

800 
700 
600 
500 
400 
300 
200 
100 
0 
Figure 5 
3 HOURS 
12 HOURS 
/ 
15 30 45 
TIME (minutes after infusion) 
_UC AGON (Absolute) 
60 
51 
/ 
500 
400 
300 
200 
100 
0 
Figure 6 
GLUCAGON (Change) 
52 

Table 4 tabulates the results of insulin assay from 
three points during the study. As the graph (Figure 7) 
illustrates, both groups showed a decline in blood 
insulin over the course of study. Although there 
is a large discrepancy between initial values in the 
two groups, because of large standard errors in the early 
group, these differences were not significant. 
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Table 4 
INSULIN ( (J.U/m.1 ) 
3 HOURS (Absolute) 
TIME MEAN STD. DEV. STD. ERR. 
0 151.50000 221.70758 128.00293 
30 92.33333 45.34681 26.18099 
60 30.66667 4.04145 2.33333 
12 HOURS (Absolute) 
TIME MEAN STD. DEV. STD„ ERR 
0 66.65750 42.75651 21.37826 
30 44.76400 51.91367 23.21650 
60 22.16400 10.66775 4.77076 
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